Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2024 NCCN Annual Conference
European Association of Urology Congress 2024
AACR Annual Meeting 2024
2024 Miami Breast Cancer Conference
2024 Society of Surgical Oncology Annual Meeting
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer,Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer
«
1
»
Advertisement
Advertisement
May
09
Today In Oncology
Addition of Durvalumab to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer PROs in TOPAZ-1
Omission of Axillary Dissection After Nodal Downstaging With Neoadjuvant Chemotherapy in Breast Cancer
Local Recurrence of Endometrial Cancer Radiotherapy With or Without Cisplatin
Historical Community Outreach and Engagement Efforts at NCI-Designated Cancer Centers
Newly Identified Biomarkers May Improve Diagnosis and Treatment of RCC Subtypes
View More
Advertisement
